文献速递肝病

SOF/VEL/VOX治疗既往DAA失败慢性丙肝的真实世界疗效与安全性

Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
PubMed 文献 · J Hepatol · 2019-06-14

这项前瞻性多中心研究评估了SOF/VEL/VOX用于既往DAA治疗失败的慢性HCV感染患者的疗效与安全性,共纳入137例患者。总体SVR12为95%,但肝硬化患者(89%,p=0.05)和GT3感染者(80%,p<0.001)的SVR12较低,GT3合并肝硬化者最低(69%)。不良反应轻微且非特异性。

要点

  • SOF/VEL/VOX再治疗总体SVR12达95%,疗效高。
  • 肝硬化患者SVR12为89%(p=0.05),低于无肝硬化者。
  • GT3感染者SVR12为80%(p<0.001),GT3合并肝硬化者仅69%。

核心结论

  • 真实世界数据显示SOF/VEL/VOX是既往DAA治疗失败患者有效、安全的挽救治疗,尽管存在耐药相关替代。
  • 肝硬化合并GT3感染患者仍是最难治疗的人群。

研究设计与样本

  • 前瞻性多中心研究,评估SOF/VEL/VOX再治疗既往DAA治疗失败患者的疗效。
  • 共纳入137例患者,75%为男性,35%有肝硬化,多数感染HCV GT1或GT3。
  • 主要终点为治疗结束后12周SVR(SVR12),同时记录安全性和耐受性数据。

主要发现

  • 136例(99%)患者治疗结束时HCV RNA检测不到。
  • 达到SVR12评估的135例患者总体SVR12为95%。
  • 肝硬化患者SVR12为89%(p=0.05),低于无肝硬化患者。
  • GT3感染者SVR12为80%(p<0.001),低于非GT3感染者。
  • GT3感染合并肝硬化患者SVR12最低,为69%。

关键数值与推荐

  • 未达到SVR12的患者中,1例再感染,7例治疗失败(6例GT3,1例GT1a)。
  • 耐药相关替代的存在未影响SVR12。
  • 不良反应轻微且非特异性。

临床怎么用

  • SOF/VEL/VOX可作为既往DAA治疗失败患者的挽救治疗方案。
  • 对于肝硬化合并GT3感染患者,需关注其较低的SVR12率。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Around 5% of patients with chronic hepatitis C virus (HCV) infection treated with direct-acting antiviral (DAA) agents do not achieve sustained virological response (SVR). The currently approved retreatment regimen for prior DAA failure is a combination of sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX), although there is little data on its use in clinical practice. The aim of this study was to analyse the effectiveness and safety of SOF/VEL/VOX in the real-world setting. METHODS: This was a prospective multicentre study assessing the efficacy of retreatment with SOF/VEL/VOX in patients who had experienced a prior DAA treatment failure. The primary endpoint was SVR 12 weeks after the completion of treatment (SVR12). Data on safety and tolerability were also recorded. RESULTS: A total of 137 patients were included: 75% men, 35% with liver cirrhosis. Most were infected with HCV genotype (GT) 1 or 3. The most common prior DAA combinations were sofosbuvir plus an NS5A inhibitor or ombitasvir/paritaprevir/r+dasabuvir. A total of 136 (99%) patients achieved undetectable HCV RNA at the end of treatment. Overall SVR12 was 95% in the 135 patients reaching this point. SVR12 was lower in patients with cirrhosis (89%, p = 0.05) and those with GT3 infection (80%, p <0.001). Patients with GT3 infection and cirrhosis had the lowest SVR12 rate (69%). Of the patients who did not achieve SVR12, 1 was reinfected and 7 experienced treatment failure (6 GT3, 1 GT1a). The presence of resistance-associated substitutions did not impact SVR12. Adverse effects were mild and non-specific. CONCLUSION: Real-world data show that SOF/VEL/VOX is an effective, safe rescue therapy for patients with prior DAA treatment failure despite the presence of resistance-associated substitutions. However, patients with liver cirrhosis infected by GT3 remain the most-difficult-to-treat group. LAY SUMMARY: Treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for 12 weeks is the current recommendation for the 5% of patients infected with HCV who do not achieve eradication of the virus under treatment with direct-acting antivirals. In a Spanish cohort of 137 patients who failed a previous combination of direct-acting antivirals, a cure rate of 95% was achieved with SOF/VEL/VOX. Genotypic characteristics of the virus (genotype 3) and the presence of cirrhosis were factors that decreased the rate of cure. Treatment with SOF/VEL/VOX is an effective and safe rescue therapy due to its high efficacy and very good safety profile.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Llaneras J, Riveiro-Barciela M, Lens S, et al. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J Hepatol. 2019. PMID: 31203153. doi:10.1016/j.jhep.2019.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。